Myotonic dystrophy is an autosomal dominant disorder, with manifestations ranging from a baby affected at birth who is both mentally and physically handicapped to an adult with lenticular opacities only. In order to give helpful genetic counselling to patients it is useful to know the risk of having a severely affected child, since this is clearly of more concern to a family than the risk of recurrence of an adult onset disorder.
In this study I have made a distinction between babies with neonatal symptoms and those who have no neonatal symptoms but who are clearly congenitally affected because they have talipes equinovarus at birth. I have done this because the neonatal form of the disease is often so dramatic, with severe respiratory problems, even apnoea, at birth and with natural improvement if the baby survives. The temporary nature of these symptoms, and their invariable occurrence in offspring of affected mothers, leads one to postulate a mechanism akin to transitory neonatal myasthenia.
Previous studies'-4 have shown that neonatal myotonic dystrophy occurs among the offspring of females who have an unusually early distribution of Received for publication 17 February 1982. ages of onset, for such females nearly always have signs of disease at the time of their pregnancies, although the mean age of onset of disease in randomly selected patients is about 30 years. 5 Other points arising out of these studies of neonatal cases are that the risk of recurrence of neonatal myotonic dystrophy after the first case is high4 and is found not only for further offspring of an affected mother, but also for the offspring of her affected sisters.6 It is also clear that only a proportion of female patients who develop myotonic dystrophy before, say, the age of 30 have children with the neonatal form of the disease. In other words, some affected females and their sisters appear to be at high risk, while other affected females do not.
It was therefore planned to study the empirical risks for congenital disease, with or without neonatal symptoms, among the offspring of both male and female patients who themselves had onset of disease before the age of 30 years. It was also planned to see if it was possible to identify those patients who had a higher than usual risk of having a congenitally affected child. Such possible methods of identifica-S Bltudey the greatest lowering of IgG was found in the families where there were congenital cases5). It was also planned to observe the fertility of the index patients, and in conjunction with these observations, estimations were made of the levels of follicular stimulating hormone (FSH), luteinising hormone (LH), and testosterone in male patients.
Once the study was commenced it became clear that there were clinical differences between the index patients. The study was therefore extended to see if these clinical differences represented genetic heterogeneity.
Methods
A search was made for patients who had developed, by the age of 30, symptoms which ultimately led to a neurological consultation. All neurologists in the West Midlands were asked for names of patients; names of patients were also found in the in-patient diagnostic indices of the five general hospitals, one neurological hospital, and one children's hospital of the Birmingham Area Health Authority; in the inpatient diagnostic index of the Coventry and Warwickshire Hospital; in the diagnostic index (covering both in-patients and out-patients) of the Neurological Department of the North Staffordshire Royal Infirmary; in the records of the Department of Clinical Genetics; and finally in the records of the three electrodiagnostic units in Birmingham.
All patients ascertained had had their diagnosis confirmed by a consultant neurologist on the basis of a muscular dystrophy (affecting the face as well as limbs), myotonia on clinical examination as well as on electromyography, and, in most cases, other features such as testicular atrophy and lenticular opacities. The medical records of the patients were scrutinised, and patients were excluded if they had onset after the age of 30 (50 patients) or if they were ascertained solely because they had an affected relative. Ten patients with neonatal myotonic dystrophy, two patients with congenital onset and no neonatal symptoms, and two patients with childhood onset were excluded because they were still children. These 14 patients could not supply information on the risks to offspring. Moreover, it was felt that the ten neonatal patients could not be considered representative of myotonic dystrophy patients in general, because of the possibility of an intrauterine factor affecting their presentation and subsequent development.1 2 A total of 48 names of patients with symptoms of myotonic dystrophy before the age of 30 was thus obtained (table 1) . Permission to approach the patients was received from the consultants and general practitioners concerned. However, 13 The interval between first symptom and first seeking medical attention was longer for type 2 patients than for type 1 patients: 14.9 years compared to 11 -2 years. Of the eight patients who waited Testosterone levels ( nmol/ I ) ""Z'Z'Z'z'":..l~. 
Discussion
Genetic heterogeneity in myotonic dystrophy has been postulated before,9 when high correlation coefficients for ages of onset were observed for pairs of first degree relatives. The correlation coefficient for all sib pairs was 0.81, which was significantly different from 0.5. (If the correlation coefficient had been consistent with 0 5 then the likely explanation would be that the intrafamilial resemblances were the result of many modifying genes. The fact that the coefficient was significantly greater than 0 5 suggested that a different main gene was present in some families.) When the sib pairs belonging to index patients who had symptoms at birth or in infancy were removed, the correlation for the remaining sib pairs was still above 0 5 at 0.64, but not significantly higher. The correlation coefficient dropped below 0 5 to 0 45 once the sib pairs belonging to index patients with onset under 20 were removed, s8ggesting that there was now homogeneity in the remaining families. Thus there was evidence for at least two, and possibly three, different main genes for myotonic dystrophy. Grimm10 also found a sib-sib correlation coefficient for age of onset that was significantly higher than 0 5, but his interpretation of the data was different. Both Bundey and Carter9 and Grimm10 found correlation coefficients for ages of onset for parent/index patient and index patient/child pairs that were higher than 0-5, though not significantly so. As well as this statistical evidence for heterogeneity clinical evidence for heterogeneity in myotonic dystrophy has come from Labrador." In this family the patients frequently presented with epiphora and reduced frequency of blinking, the male patients did not suffer from hair loss or testicular atrophy, the female patients had a high incidence of obstetric complications, and there was no lowering of IgG levels, but instead a reduction of IgA levels. No patient resembling the Labradorean type of myotonic dystrophy was seen in the present study.
There are two main pieces of evidence for heterogeneity in myotonic dystrophy in the present study.
The first is that the age of onset distribution for the 35 index patients shows bimodality (fig 1) , suggesting that two entities might be present. The bimodality would be more striking if the six neonatal cases seen were included in the figure. The bimodality roughly corresponds to type 1 and type 2 patients.
The second piece of evidence is that the clinical differences which divided 30 of the 35 patients into two groups were reflected in their affected relatives. All but one affected relative (a parent) belonged to the same clinical category as the index patient. The explanation for this exceptional family could be that the mother was incorrectly classified as type 2 or that her two sons were incorrectly classified as type 1. It is difficult to explain the remaining intrafamilial resemblances by a common family environment. I conclude that there is a genetic basis for the observed clinical differences, and in view of the other evidence (high correlation coefficients for ages of onset and bimodality of ages of onset), it is likely that there are different main genes for myotonic dystrophy.
An alternative explanation is that age of onset determines the type of disease that develops. This would be surprising in view of the fact that the earliest onset (excluding cases with superimposed neonatal symptoms) have a milder form of disease. Also, such a hypothesis would not explain either the very high correlation coefficients observed9 or the bimodality for age of onset.
Another possible explanation for the clinical heterogeneity is the observation by Harper'2 that an affected woman appears to influence the severity and onset of disease of her offspring, not only with regard to neonatal affection, but also in relation to onset in childhood. However, in the present series, there was no significant excess of affected mothers of type 2 cases (seven mothers: six fathers). Also, among the parents of probands who developed symptoms before the age of 20, there were nine mothers and nine fathers.
Once the index patients had been classified into two types on the basis of the distribution and relative severity of muscle weakness, observations could be made on secondary features of the two types of myotonic dystrophy, and these have been summarised in table 7. The association of mental retardation and early loss of reflexes with type 2 myotonic dystrophy raises the possibility of neuronal degeneration in this disorder. The study suggests that type 2 myotonic dystrophy is more common than type I myotonic dystrophy, when considering this group of index patients with onset under 30. However, we do not know the classification of the seven patients who were ascertained but who had died before the outset of the study, and it is possible that the majority of these could have had type 1 disease in view of its greater severity and shorter duration.
The other aim of this study was to observe prospectively the empirical risk for neonatal myotonic dystrophy occurring in the offspring of patients with onset before the age of 30. The overall risk has been shown to be in 7 in 38, but the risk was confined to the offspring of affected females, 7 out of 27. Although neonatal symptoms are restricted to the offspring of affected women, congenital myotonic dystrophy without neonatal symptoms may occur among the offspring of both affected males and females. Three index patients in this study had congenital talipes: one had an affected mother, one had an affected father, and for the other it was not known which of the two dead parents was affected, but one of them must have been as the index patient had an affected brother. Mental retardation necessitating education at a special school could be considered a manifestation of congenital onset; the three mentally retarded index patients in the study had two affected mothers and one affected father. The fact that males with type 2 myotonic dystrophy have about one-sixth the fertility of females with type 2 myotonic dystrophy is probably sufficient to account for the fact that congenitally affected patients (with or without neonatal symptoms) are more commonly found to have affected mothers. 
